Codex DNA to Report First Quarter 2022 Financial Results on Tuesday, May 10, 2022

Rhea-AI Summary

Codex DNA, Inc. (Nasdaq: DNAY) will release its Q1 2022 financial results on May 10, 2022, after market close. A conference call will follow at 1:30 p.m. PT to discuss results and corporate highlights. Investors can access the release and live webcast via their website. Codex DNA is recognized for its innovative synthetic biology solutions, including the BioXp™ system, which enables rapid and accurate DNA synthesis for various applications like precision medicine and genome editing.

Positive

• Codex DNA is a pioneer in synthetic biology with the BioXp™ system for rapid DNA synthesis.
• The upcoming earnings report could provide valuable insights into the company's growth and market position.

Negative

• None.

SAN DIEGO, May 03, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that it will release its first quarter 2022 financial results on Tuesday, May 10, 2022, after the market closes. In conjunction with the release, management will host a conference call on Tuesday, May 10, 2022, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the financial results and recent corporate highlights.

The press release and live audio webcast can be accessed via the Investor section of the Company’s website at www.codexdna.com. The conference call can be accessed by dialing (888) 705-0127 (domestic) or (409) 937-8880 (international) and referring to conference ID 7942349. Please log in approximately 5 to 10 minutes before the event to ensure a timely connection. The archived webcast will remain available for replay on Codex DNA’s website for 30 days.

About Codex DNA

Codex DNA is empowering scientists with the ability to create sustainable, synthetic biology solutions for many of humanity’s greatest challenges. As inventors of the industry-standard Gibson Assembly^® method and the first commercial automated benchtop DNA and mRNA synthesis system, Codex DNA is enabling rapid, accurate, and reproducible writing of DNA and mRNA for numerous downstream markets. The company’s award-winning BioXp™ system consolidates, automates, and optimizes the entire synthesis, cloning, and amplification workflow. As a result, it delivers virtually error-free synthesis of DNA/RNA at scale within days and hours instead of weeks or months. Scientists around the world are using the technology in their own laboratories to accelerate the design-build-test paradigm for novel, high-value products for precision medicine, biologics drug discovery, vaccine and therapeutic development, genome editing, and cell and gene therapy. Codex DNA is a public company based in San Diego. For more information, visit codexdna.com.

Contact:
Richard Lepke
Director of Investor Relations
(619) 840-5392
RichardL@codexdna.com

FAQ

When will Codex DNA release its Q1 2022 financial results?

Codex DNA will release its Q1 2022 financial results on May 10, 2022, after market close.

What time is the Codex DNA conference call scheduled?

The conference call is scheduled for May 10, 2022, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

How can I access the Codex DNA Q1 2022 earnings call?

The earnings call can be accessed by dialing (888) 705-0127 for domestic calls or (409) 937-8880 for international calls, using conference ID 7942349.

What technology does Codex DNA utilize in synthetic biology?

Codex DNA uses the BioXp™ system for streamlined and efficient DNA and mRNA synthesis.

What are the applications of Codex DNA's technology?

Applications include precision medicine, biologics drug discovery, vaccine development, and genome editing.